Aberrant expression of the Evi1 (ecotropic virus integration site 1) proto-oncogene has been associated with hematopoietic malignancies in both mice and man. To determine the effect of enforced expression of Evi1 in vivo, we developed a transgenic mouse model utilizing the murine Sca-1 (Ly-6E.1) promoter. Here, we describe the generation and analysis of three independent lines of Evi1 transgenic mice. Transgenic animals of two founder lines developed normally. These mice did not show any obvious hematological abnormalities but showed a significant reduction in the number of bone marrow colony-forming unit erythroid (CFU-E)-derived colonies. This implies a defect of normal erythroid hematopoiesis affecting relatively late erythroid progenitor cells. We also show that when newborn Evi1 transgenic mice of these two lines were infected with Cas-Br-M MuLV, tumor incidence was greatly enhanced in comparison with nontransgenic littermates, indicating an increased susceptibility for leukemia development. Interestingly, analysis of a third founder line revealed that all male progeny consistently displayed severely impaired erythropoiesis with major defects in the bone marrow, spleen and peripheral blood. Taken together, our results present the first evidence of Evi1 disturbing normal erythropoiesis in vivo and provides evidence for cooperative potential of Evi1 in tumor progression. Leukemia (2000) 14, 1876-1884.
Introduction
The Evi1 (ecotropic virus integration site 1) gene was originally identified as a proto-oncogene activated in murine myeloid leukemias by retroviral insertional mutagenesis. 1 Transcriptional activation of the human EVI1 gene occurs in myeloid leukemias and myelodysplastic syndromes as a consequence of chromosomal translocations and insertions involving chromosome band 3q26, [2] [3] [4] [5] where the gene is located. 6 Abnormal expression of EVI1 has also been demonstrated in patients with a normal karyotype, [7] [8] [9] suggesting that activation of the Evi1 gene may occur via other mechanisms as well. The Evi1 gene encodes a nuclear 145 kDa Cys 2 His 2 -type zinc finger (ZF) protein that contains two separate domains of DNA-binding zinc fingers. 1 The N-terminal domain (ZF1-7) recognizes the sequence GA(C/T)AAGA (T/C)AAGATAA. 10, 11 Interestingly, this recognition site shows overlap with the recognition sequence identified for the GATA family of transcription factors 12, 13 of which GATA-1 and GATA-2 play pivotal roles in normal erythropoiesis. 14 From in vitro studies it is apparent that Evi1 is a proto-oncogene capable of disturbing normal cellular proliferation and differentiation in certain cell types. Ectopic expression of Evi1 in 32DEpo as well as in murine primary bone marrow cells has been shown to lead to a loss of EPO responsiveness of these cells. 15 Overexpression of Evi1 in 32Dcl3 cells resulted in loss of G-CSF-dependent survival and maturation of these cells. 16 The exact mechanism, however, by which Evi1 exerts these biological activities remains to be elucidated. The overall structure of Evi1 suggests a potential role as a transcriptional regulator for this protein. 1 Although Evi1 has been described as a possible transcriptional activator, 17, 18 Evi1-mediated repressor activity has also been reported. 15, [19] [20] [21] With respect to the latter, Evi1-mediated repression of a (subset) of GATAtarget genes has been proposed as a putative mechanism of action. 15 Recently, on the other hand, perturbation of transforming growth factor-␤ (TGF-␤) signalling has also been proposed as a repressive mechanism of action by which Evi1 may contribute to leukemogenesis. 22, 23 To investigate the role of Evi1 in hematopoietic dysregulation and to study its effect in hematopoietic malignancies in vivo we generated Evi1 transgenic mice. These mice bear the Evi1 gene under the control of the Sca-1 (Ly-6E.1) promoter, 24 to target expression of Evi1 to all hematopoietic lineages during hematopoietic development. The use of this promoter construct has been shown to confer transgenic expression in early hematopoiesis. 25 In this study, we show by using this promoter that enforced expression of the Evi1 proto-oncogene leads to erythroid defects in transgenic mice. In analogy with other transgenic mouse models [26] [27] [28] we subjected Evi1 transgenic mice to a retroviral insertional mutagenesis approach to investigate the cooperative potential of the Evi1 gene in leukemogenesis. We demonstrate that ectopic expression of Evi1 confers enhanced susceptabilty to Cas-Br-M MuLVinduced tumorigenesis in these mice, thereby suggesting a collaborating oncogenic role for Evi1 in multistep tumor development.
Materials and methods

Construction of the Evi1 transgene
An Evi1 expression vector was constructed containing the fulllength murine Evi1 cDNA under the control of regulatory elements of the murine Sca-1 (Ly-6E.1) gene. A 4.5-kb EcoRI cDNA fragment encompassing the complete coding region was isolated from the Evi1 cDNA clone p58-2 1 and was filled in with the Klenow fragment of DNA polymerase I. The resulting fragment was cloned into the ClaI site of pL6Cla (a gift from Dr E Dzierzak, Department of Cell Biology and Genetics, Erasmus University Rotterdam, Rotterdam, The Netherlands) to yield pSca/Evi1. The plasmid pL6Cla contains the full-length 14-kb Sca-1 (Ly-6E.1) gene. 25 The proper orientation of the Evi1 cDNA insert was verified by restriction enzyme analysis.
Generation and propagation of transgenic mice
Transgenic mice were engineered according to standard techniques. 29 A linearized DNA fragment of 18.5 kb in length was derived by NotI digestion of pSca/Evi1 (see above) and purified by means of 0.8% agarose gel electrophoresis and electro-elution. This DNA fragment was microinjected into the most accessible pronucleus of (FVBxFVB) fertilized mouse eggs. These eggs were re-implanted into pseudo-pregnant BCBA female foster mice. Transgenic mice were identified by Southern blot analysis of tail-derived DNA according to standard procedures. 30 In short, DNA was isolated, digested with BglII, electrophoresed in a 0.8% agarose gel and transferred to Hybond-N + nylon membranes (Amersham Pharmacia Biotech Benelux, Roosendaal, The Netherlands) with 0.25 M NaOH/1.5 M NaCl. Membranes were hybridized with a random-primed 32 P-labeled 0.3-kb DNA fragment spanning nt 540-869 (ZF1-3) of the murine Evi1 gene. 1 Transgenic founder mice were bred with normal FVB mice to establish transgenic lines. All mice were maintained under standard conditions and treated according to institutional animal health care and use guidelines.
RNase protection analysis
Total cellular RNA was prepared from bone marrow, spleen, and thymus by homogenizing tissue cells in 4M guanidium thiocyanate, followed by phenol-chloroform extraction and isopropanol precipitation. 30 The RNA samples were subjected to an RNase protection assay, essentially as described by the supplier (Promega, Leiden, The Netherlands). For this purpose ZF1-3 (see above) of the Evi1 gene was cloned into a pBlueskript II SK+ vector with flanking T 3 and T 7 sequences to yield pBlue/Evi1ZF1-3. To synthesize an antisense 350-bp riboprobe, pBlue/Evi1ZF1-3 was cut with HindIII and transcribed by means of T 7 polymerase. For comparison of the signals a radiolabeled GAPDH riboprobe was synthesized. 31 After hybridization overnight at 50°C, samples were digested with RNase One (Promega) and electrophoresed in a 6% polyacrylamide-8 M urea sequencing gel. After running, the gels were dried and exposed for autoradiography with a Kodak film and an intensifying screen.
Hematopoietic colony formation assays
Bone marrow cells were harvested by crunching femurs and tibia of Evi1 transgenic and nontransgenic control mice. Single cell suspensions were washed twice in HBSS (Hanks'; GIBCO Life Technologies, Gent, Belgium) and resuspended in ␣-minimum essential medium (␣-MEM; GIBCO Life Technologies). Bone marrow cells were plated at 0. mol/l hemin, 100 ng/ml rSCF, 3 U/ml Epo. Dishes were incubated at 37°C in 5% CO 2 . Assays were performed in triplicate. Colonies were counted at day 2 (CFU-E-derived colonies), day 14 (BFU-E-derived colonies) using an inverted microscope.
Leukemia
Peripheral blood cell counts and bone marrow analysis
Peripheral blood (PB) was collected in EDTA-coated microtubes (SARSTEDT, Etten-Leur, The Netherlands) by heart or tail puncture. Peripheral blood counts and hematological parameters were determined using an automated blood cell counter (Cobas, ABX La France, Montpellier, France). For reticulocyte counts, 30 l of collected peripheral blood was diluted 1:4 in HBSS (GIBCO Life Technologies) and measured with an automated reticulocyte analyzer (Sysmex K-3000; Toa Medical Electronics, Kobe, Japan). Differential counts of peripheral blood and bone marrow cells were performed microscopically on May-Grü nwald-Giemsa stained smears and cytospins, respectively.
Histopathology
Dissected spleens were fixed in 10% phosphate-buffered formalin and embedded in paraffin. Femur bone samples were decalcified prior to fixation and embedding. Thin tissue sections were stained with hematoxylin and eosin for histological examination according to standard procedures.
Tumor induction, immunophenotyping and DNA analysis
For tumor induction Cas-Br-M MuLV was used to infect Evi1 transgenic mice and nontransgenic littermates. Cas-Br-M MuLV producing NIH 3T3 cells (a gift from Dr J Hartly) were cultured in Dulbecco's modified Eagle's medium (DMEM; GIBCO Life Technologies) containing 10% fetal calf serum (FCS). A subconfluent culture of Cas-Br-M MuLV-producing NIH 3T3 cells was incubated in 5 ml of culture medium for 18 h at 37°C, in a 75 cm 2 culture flask. Newborn mice were injected subcutaneously with 100 l filtered (pore size, 0.22 m; Nucleopore, Pleasanton, CA, USA) tissue culture medium. Mice were sacrificed when moribund. Tumor tissues, ie bone marrow and spleen, were isolated and cryopreserved and stored in liquid nitrogen. Single-cell suspensions of spleen tumor cells were analyzed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). Cells were analyzed using rat monoclonal antibodies. Detection of bound antibodies was performed using GARa (goat-anti-Rat)-FITC (Nordic, Tilburg, The Netherlands) reagent. Specificities of the antibodies used were as follows: ER-MP58 (anti-ER-MP58); M1/70 (anti-Mac-1); F4/80 (anti-F4/80); RB68C5 (anti-Gr1); 59-AD2.2 (anti-Thy1); KT-3 (anti-CD3); E13161-7(anti-Sca1); CD34 (anti-CD34). For Southern blot analysis tumor spleen DNA was digested with BamHI and analyzed as described above. To generate a CasBr-M MuLV-specific LTR probe, DNA was isolated from NFS78 which is an in vitro established cell line from a Cas-Br-M MuLV-initiated primary tumor. 32 A 518 nt Cas-Br-M MuLVspecific LTR fragment was generated by PCR and used for hybridization.
Statistical analysis
Statistical analysis was performed for colony-forming assay data, peripheral blood cell counts, reticulocyte counts and differential bone marrow counts. The significance of differences between groups was evaluated using the two-tailed Student's t-test. Values of P Ͻ 0.05 were considered significant and indicated in legends when appropriate.
Results
Generation of Evi1 transgenic mice and analysis of transgene expression
To generate Evi1 transgenic lines expressing the Evi1 protooncogene, an expression vector was constructed containing the full-length murine Evi1 cDNA under the control of the Sca-1 promoter (Ly-6E.1) (Figure 1a) . From subsequent microinjection of linearized transgene DNA into fertilized oocytes, three transgenic founder animals were obtained as identified by Southern blot analysis using an Evi1-specific probe (Figure 1b) . Founders No. 8, No. 11 and No. 14 were estimated to carry 4, 12 and 16 transgene copies, respectively. From these founders three independent lines (No. 8, No. 11, No. 14) were established. Since Evi1 protein was not detectable by immunoblot analysis in hematopoietic tissues (data not shown) we performed an RNase protection assay. To monitor mRNA expression of the Evi1 transgene and compare the levels of Evi1 mRNAs in hematopoietic tissues between the transgenic lines, total cellular RNA was extracted from bone marrow, spleen and thymus and analyzed. Using a 350-nt antisense Evi1-specific RNA probe, transgenic Evi1 expression was detected in bone marrow, spleen, thymus in all three transgenic lines, whereas no Evi1 transcripts could be detected in these tissues of nontransgenic control mice (Figure 1c ). Although some variation between different experiments was apparent, no obvious differences in levels of Evi1 mRNA were observed either between the different transgenic lines or between the different hematopoietic tissues examined. 
No overt hematopoietic abnormalities in Evi1 transgenic mice
bled on a monthly basis. Peripheral blood cell examinations revealed no changes or abnormalities in both the total number and circulating subsets of blood cells and reticulocyte counts (Figure 2a, b) of these animals. No apparent changes in hemoglobin, hematocrit, and platelet values (data not shown) were observed in comparison with nontransgenic littermates, indicating that the hematopoietic profile of these mice was normal. Gross examination as well as histological and pathological analysis of hematopoietic organs, ie bone marrow spleen and thymus, did not show any obvious abnormalities (data not shown).
Alteration in clonogenic capacities of erythroid progenitor cells of Evi1 transgenic mice
We analyzed the clonogenic capacities of different types of hematopoietic progenitor cells in the bone marrow of Evi1 transgenic mice in colony formation assays. The number of CFU-E-derived colonies in Evi1 transgenic bone marrow was significantly reduced compared with CFU-E numbers in nontransgenic control littermates (Figure 3 ). The numbers of more immature BFU-E-derived colonies in transgenic bone marrow did not differ from those in nontransgenic control animals ( Figure 3 ). No differences were observed in values of CFU-G, CFU-GM and CFU-MK bone marrow-derived colonies between transgenic and nontransgenic control animals (data not shown). These results indicate that a mild phenotype occurs in line No. 8, No. 11 and female No. 14 Evi1 transgenic mice, implying an impairment of the clonogenic growth of relatively late committed erythroid progenitors.
Increased tumor incidence by Cas-Br-M MuLV in Evi1 transgenic mice
To further investigate the role of Evi1 in tumor formation and to study its potency as a collaborating proto-oncogene in tumor progression, new-born transgenic mice from line No. 8, No. 11 and nontransgenic littermates were infected with Cas-Br-M MuLV. Animals were monitored for tumor development. Mice were sacrificed when they became terminally ill, and analyzed. Fifteen months after retroviral infection 15 out of 31 (48%) Evi1 transgenic mice had developed leukemia whereas in only four out of 39 (10%) of nontransgenic control littermates leukemia was observed. This difference is indicative of an enhanced susceptibility for Cas-Br-M MuLV-induced tumor formation in Evi1 transgenic mice suggesting oncogenic collaborating potential for Evi1 (Figure 4a) . Autopsy of moribund animals revealed enlarged spleens in all cases.
Immunophenotyping by FACS analysis of spleen tumors for lineage-specific markers revealed that they were mainly from a myeloid origin (Table 1) . Analysis of both the spleen and
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Figure 2
Composition of peripheral blood cells in Evi1 transgenic mice and nontransgenic control mice. (a) Erythrocytes (left), reticulocytes (right). The percentage of reticulocytes in male line No. 14 mice differed significantly from healthy transgenic and nontransgenic control mice (P Ͻ 0.05, two-tailed Student's t-test). (b) Neutrophilic granulocytes (left) and lymphocytes (right). Significant differences in values of neutrophils as well as lymphocytes were determined between male line No. 14 mice and healthy transgenic and nontransgenic control mice, using two-tailed Student's t-test, P Ͻ 0.05. Values are expressed as indicated in Figure 2 . Group 1, nontransgenic control mice; group 2, healthy mice line No. 8, No. 11, No. 14; group 3, male line No. 14 mice (severe erythroid defects).
bone marrow of these animals showed an elevated percentage of blasts (Table 1 ). The hematopoietic profile as determined from blood smears revealed that these mice were severely anemic. In addition, there was a strong reduction of the white blood cell count (Table 1) with reductions in both lymphocyte and granulocyte cell populations (data not shown). RNase protection analysis demonstrated the presence of Evi1 mRNA transcripts in these spleen tumors (Figure 4b ) implying both the involvement and requirement of Evi1 in the onset of these tumors. DNA samples from these spleen tumors were analyzed by Southern blot analysis using a Cas-Br-M MuLV-specific LTR probe. Hybridization with the LTR probe showed distinct proviral integration patterns in independent tumor tissues ( Figure 5 ).
Figure 3
Colony-forming assays of bone marrow cells in Evi1 transgenic mice. Bone marrow cells were isolated from Evi1 transgenic mice and nontransgenic littermates plated and cultured in triplicate in methylcellulose as described in the Materials and methods section. Colonies were counted on day 2 (CFU-E, right) and day 14 (BFU-E, left). Each point in each column represents data obtained from a single mouse from each group. Values are expressed as the mean number of colonies counted. Group 1, nontransgenic control mice; group 2, healthy mice line No. 8, No. 11, No. 14; group 3, male line No. 14 mice (severe erythroid defects). Significance of differences in CFU-E numbers (P Ͻ 0.05) between control mice vs healthy transgenic and male line No. 14 mice, respectively, were determined using the two-tailed Student's t-test.
Severe erythroid defects in male progeny transgenic line No. 14
All male progeny of transgenic line No. 14 male mice died between 50 and 80 days after birth. It is noteworthy that the Evi1 transgene in this particular line is X-linked as determined by FISH analysis (data not shown) and contains the highest transgene copy number. At birth male line No. 14 progeny were phenotypically indistinguishable from their control littermates. At 4-6 weeks after birth these mice became ill and expressed characteristic symptoms: a hunched posture, ruffled hair, diarrhea and weight loss. In addition, these animals were infertile. Animals were sacrificed when moribund, usually within 2 weeks after the first signs of sickness and hematopoietic and other tissues were examined. At autopsy, gross examination of these animals revealed a reduction of the spleen varying from 50 to 75% of the normal size. In addition, the spleen appeared less hemoglobinized compared with a normal spleen (Figure 6a) . Histological examination displayed a grossly abnormal splenic architecture characterized by the loss of virtually all red pulp and the absence of erythroblasts. Furthermore, in most cases affected areas of the spleen were markedly infiltrated by neutrophils (Figure 6b) . Analysis of the bone marrow of these mice revealed a strong reduction in the percentage of erythroblasts and also an infiltration with neutrophils (Figure 7a, b) . These results indicate a severe general impairment of erythroid hematopoiesis in these mice. This is consistent with a reduced percentage of reticulocyte counts that we observed in these animals. However, the circulating number of red blood cells was normal. Blood parameters for these particular male line No. 14 mice were monitored on a weekly basis. No hematological abnormalities other than as described above were observed in these animals just prior to their death. In addition, in vitro colony assays revealed that bone marrow CFU-E numbers were significantly reduced to (Figure 2) . Interestingly, although the mice displayed a severe erythroid defect, BFU-E-derived colony numbers in the bone marrow of these mice did not differ from nontransgenic control values. Similar to line No. 8, No. 11 and female line No. 14 progeny, no differences in growth of colonies of myeloid origin were observed (data not shown) compared to nontransgenic animals.
Discussion
The Evi1 proto-oncogene has been implicated in hematopoietic malignancies in both man and mice. To establish an in vivo model and investigate the effect of ectopic expression of Evi1 in normal hematopoiesis we generated three lines of Evi1 transgenic mice. Evi1 expression was driven by the Sca-1 (Ly-6E.1) promoter, which directs expression in hematopoietic stem and progenitor cells. [33] [34] [35] Since the involvement of aberrant Evi1 expression has been implicated in abnormalities in both myeloid and erythroid lineages, the use of this promoter construct allowed us to study the effect of ectopic expression of Evi1 during development of all hematopoietic lineages. In this paper, we demonstrate Evi1 mRNA expression in the bone marrow, spleen and thymus of Evi1 transgenic mice. We show that ectopic expression of Evi1 disturbs The mice are designated CFL (Cas-Br-M MuLV; FVB background; Leukemia). b In all cases splenomegaly (S) was observed. In one case a thymoma was found (T). In two cases a lymphoma (L) was observed. erythroid hematopoiesis and increases the propensity for leukemia development.
The numbers of bone marrow CFU-E-derived colonies in the progeny of all three transgenic lines was significantly reduced implying that ectopic expression of the Evi1 transgene leads to a reduced clonogenic capacity, affecting the relatively late erythroid progenitors. Despite this erythroid defect, the number of circulating red blood cells in these mice was normal. Several possibilities may be proposed to explain this finding. Hyperproliferation of erythroid precursors in the bone marrow and or spleen may compensate for an alleged erythrocyte deficiency in the peripheral blood. It is also possible that an intrinsic impairment of clonogenic capacity of these cells is compensated by an adapted microenvironment in the bone marrow only, ie production of certain cytokines by stromal and/or other accessory cells to maintain normal erythropoietic productivity. Alternatively, assuming that an excess of progenitors exist, a reduction of late erythroid progenitors which remains within certain limits may simply not affect numbers of circulating red blood cells.
When Evi1 transgenic mice, displaying the erythroid defect, were injected by Cas-Br-M MuLV, tumor incidence was greatly increased compared with nontransgenic control mice. This indicates that Evi1 transgenic mice possessed a higher susceptibility for Cas-Br-M MuLV-induced tumor formation. The latency in the onset of the tumor formation as well as the presence of Evi1 transcripts in all accelerated Cas-Br-M MuLV-induced tumors provides strong evidence for the cooperative potential of Evi1 in multistep tumor development. In this context, the observed erythroid defect affecting the clonogenic capacity as a consequence of ectopic Evi1 expression would be consistent with its being a step in multistep tumor formation. Experiments to identify putative Evi1 collaborating oncogenes in these mice are currently in progress.
An interesting result was obtained with one of the trangenic lines (No. 14) in which all male progeny eventually died between 50 and 80 days after birth while all female progeny displayed the same erythroid defect as described for all progeny of the two other lines (No. 8 and No. 11) . At the present time it is not clear what causes the sudden onset and subsequent rapid progression of the disease in this specific transgenic line. These mice possessed the highest copy number of the Evi1 transgene suggesting a transgene dosage effect. It is conceivable that at some time point during the development of these animals the Evi1 transgenic protein level rose above a certain critical threshold rendering the animals unable to cope with the severity of the phenotype. Unfortunately, we could not detect Evi1 protein in hematopoietic tissues, most likely due to the constraints of the Evi1 expression construct driving expression of Evi1 into only a small target population of Sca-1-positive cells. Nor could we detect obvious differences in expression levels of the Evi1 transgene as determined by RNase protection analysis in comparison with line No. 8, No. 11 and female No. 14 progeny (unpublished results) which did not display this severe phenotype. Death is unlikely to result from bacterial or viral infection given the housing conditions of the mice. Moreover, postmortem analysis did not reveal any evidence of bacteremia or viral infection. Death may be related to the severe wasting observed in all male line No. 14 mice. Analysis of the deceased males from line No. 14 consistently showed severely impaired erythropoiesis with major defects in the bone marrow, spleen and blood but no signs of leukemia were observed. Since these mice live too short a time to actually suffer from anemia, bone marrow failure can be excluded as the major cause of death. However, the observed phenotypic traits may reflect an early state of bone marrow failure leading to cytopenia and anemia. It is notable that in humans aberrant expression of EVI1 has been implicated in MDS (myelodysplastic syndrome). 7, 36, 37 MDS is characterized by the clinical manifestation of bone marrow failure as well as the tendency to evolve into acute leukemias. 38 Therefore, this observed phenotype in male line No. 14 mice may represent a preleukemic stage in these mice. These mice possessed the highest copy number of the Evi1 transgene which may suggest a transgene dosage effect. However, since we observed this particular phenotype in only one line, we cannot rule out the possibility of a position effect of the transgene.
At this time, we can only speculate about the molecular mechanisms responsible for the phenotypic traits that we observed in Evi1 transgenic mice. However, the simplest explanation for an impairment of the erythroid compartment, ie reduced clonogenic capacity at the CFU-E level and severely impaired erythropoiesis in all male progeny from line No. 14, would be that ectopic Evi1 expression interferes with the ability of cells to initiate and/or complete particular stages of their differentiation program. Indeed, our findings would fit a model of Evi1-mediated interference with members of the GATA family of transcription factors by repressing transcription of a subset of GATA target genes. Our findings do support the outcome of in vitro studies demonstrating the impairment of a normal response to EPO of erythroid progenitors as a result of aberrant expression of Evi1. 15 In that study, Evi1 was shown to interfere with erythroid differentiation in vitro and to compete for GATA-1-dependent transcriptional activity. 15 Although we did not show direct evidence for such interference by Evi1, its role may be more complex and affect (tightly) controlled levels of GATA-1 and/or GATA-2. In this respect, our data show similarity with a GATA-1 loss of function phenotype.
14,39 Further questions of interest will then be how Evi1 exactly interferes with these GATA factors to perturb erythroid development. Recently, Evi1 interference with TGF-␤ signaling has been proposed as a mechanism by which Evi1 contributes to leukemogenesis. 22, 23 It will be interesting to investigate whether involvement of this pathway also contributes to our observations.
